Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AHCONASDAQ:CDNANASDAQ:VMDNASDAQ:VRDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAHCOAdaptHealth$8.70-0.9%$9.48$7.11▼$11.90$1.17B1.641.27 million shs4.42 million shsCDNACareDx$15.17+1.1%$18.49$9.64▼$34.84$844.68M2.27867,021 shs1.43 million shsVMDViemed Healthcare$7.33-0.5%$7.15$6.21▼$9.81$289.71M1.49139,633 shs76,208 shsVRDNViridian Therapeutics$13.12-3.7%$13.92$9.90▼$27.20$1.07B0.571.20 million shs558,016 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAHCOAdaptHealth0.00%+4.40%-13.07%-14.26%-14.42%CDNACareDx0.00%-18.83%-13.19%-35.68%+54.32%VMDViemed Healthcare0.00%+4.24%+7.12%-8.45%-9.90%VRDNViridian Therapeutics0.00%+0.89%+13.59%-29.43%-11.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAHCOAdaptHealth3.4342 of 5 stars4.51.00.00.02.51.71.9CDNACareDx3.6044 of 5 stars3.31.00.04.23.40.80.6VMDViemed Healthcare1.6255 of 5 stars0.05.00.00.03.52.50.0VRDNViridian Therapeutics1.2222 of 5 stars3.40.00.00.03.70.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAHCOAdaptHealth 3.00Buy$13.8058.62% UpsideCDNACareDx 2.57Moderate Buy$30.3399.96% UpsideVMDViemed Healthcare 4.00Strong BuyN/AN/AVRDNViridian Therapeutics 2.75Moderate Buy$35.70172.10% UpsideCurrent Analyst Ratings BreakdownLatest VMD, VRDN, AHCO, and CDNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025CDNACareDxStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$40.00 ➝ $40.005/5/2025CDNACareDxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$25.00 ➝ $25.004/23/2025VRDNViridian TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$34.00 ➝ $34.004/17/2025CDNACareDxThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$34.00 ➝ $26.003/3/2025CDNACareDxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$26.00 ➝ $25.002/27/2025AHCOAdaptHealthRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$14.00 ➝ $16.002/27/2025CDNACareDxStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$40.00 ➝ $40.002/26/2025AHCOAdaptHealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $14.002/26/2025AHCOAdaptHealthRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$11.00 ➝ $14.002/26/2025AHCOAdaptHealthTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $14.002/13/2025AHCOAdaptHealthUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.00(Data available from 5/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAHCOAdaptHealth$3.26B0.36$10.74 per share0.81$11.06 per share0.79CDNACareDx$346.42M2.44N/AN/A$4.83 per share3.14VMDViemed Healthcare$224.26M1.29$0.77 per share9.56$2.96 per share2.48VRDNViridian Therapeutics$302K3,544.57N/AN/A$4.48 per share2.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAHCOAdaptHealth-$678.90M$0.60N/A8.971.08-6.57%9.62%3.18%5/6/2025 (Estimated)CDNACareDx-$190.28M$1.15N/AN/AN/A-45.90%-53.70%-30.42%N/AVMDViemed Healthcare$10.24M$0.2827.15∞N/A4.87%8.72%6.48%5/7/2025 (Estimated)VRDNViridian Therapeutics-$237.73M-$3.77N/AN/AN/A-85,127.16%-70.12%-41.49%5/6/2025 (Estimated)Latest VMD, VRDN, AHCO, and CDNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025VRDNViridian Therapeutics-$0.95N/AN/AN/A$0.04 millionN/A5/6/2025Q1 2025AHCOAdaptHealth$0.01N/AN/AN/A$764.77 millionN/A4/30/2025Q1 2025CDNACareDx$0.06$0.09+$0.03-$0.19$84.56 million$84.69 million2/27/2025Q4 2024VRDNViridian Therapeutics-$1.05-$0.81+$0.24-$0.81$0.05 million$0.07 million2/26/2025Q4 2024CDNACareDx$0.05$1.51+$1.46$1.51$84.56 million$86.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAHCOAdaptHealthN/AN/AN/AN/AN/ACDNACareDxN/AN/AN/AN/AN/AVMDViemed HealthcareN/AN/AN/AN/AN/AVRDNViridian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAHCOAdaptHealth1.341.241.00CDNACareDxN/A4.103.87VMDViemed Healthcare0.031.311.19VRDNViridian Therapeutics0.0418.5518.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAHCOAdaptHealth82.67%CDNACareDxN/AVMDViemed Healthcare74.24%VRDNViridian TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAHCOAdaptHealth4.43%CDNACareDx4.90%VMDViemed Healthcare20.00%VRDNViridian Therapeutics0.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAHCOAdaptHealth10,900134.87 million128.59 millionOptionableCDNACareDx74055.68 million51.01 millionOptionableVMDViemed Healthcare63039.52 million31.15 millionNot OptionableVRDNViridian Therapeutics5081.59 million78.70 millionOptionableVMD, VRDN, AHCO, and CDNA HeadlinesRecent News About These CompaniesNovo Holdings A S Sells 135,000 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 3 at 8:09 AM | marketbeat.comSchonfeld Strategic Advisors LLC Reduces Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 3 at 5:53 AM | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by Price T Rowe Associates Inc. MDMay 3 at 4:28 AM | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Barclays PLCMay 2 at 3:43 AM | marketbeat.comLord Abbett & CO. LLC Raises Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)April 30, 2025 | marketbeat.comTower Research Capital LLC TRC Raises Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)April 30, 2025 | marketbeat.comArtia Global Partners LP Purchases Shares of 100,000 Viridian Therapeutics, Inc. (NASDAQ:VRDN)April 29, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Grows Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)April 28, 2025 | marketbeat.comRaymond James Financial Inc. Makes New $6.02 Million Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN)April 27, 2025 | marketbeat.comJ. Safra Sarasin Holding AG Takes $699,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)April 26, 2025 | marketbeat.comViridian Therapeutics' (VRDN) "Buy" Rating Reiterated at HC WainwrightApril 26, 2025 | americanbankingnews.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 25, 2025 | marketbeat.comViridian Therapeutics' (VRDN) Buy Rating Reiterated at HC WainwrightApril 25, 2025 | marketbeat.comSilverarc Capital Management LLC Purchases Shares of 100,000 Viridian Therapeutics, Inc. (NASDAQ:VRDN)April 24, 2025 | marketbeat.comDiadema Partners LP Purchases Shares of 49,478 Viridian Therapeutics, Inc. (NASDAQ:VRDN)April 24, 2025 | marketbeat.comEversept Partners LP Buys 88,766 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)April 24, 2025 | marketbeat.com22,972 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Purchased by XTX Topco LtdApril 24, 2025 | marketbeat.comVivo Capital LLC Sells 695,631 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)April 23, 2025 | marketbeat.comRenaissance Technologies LLC Has $7.12 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)April 21, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by JPMorgan Chase & Co.April 20, 2025 | marketbeat.comGeode Capital Management LLC Has $31.81 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)April 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVMD, VRDN, AHCO, and CDNA Company DescriptionsAdaptHealth NASDAQ:AHCO$8.70 -0.08 (-0.91%) Closing price 04:00 PM EasternExtended Trading$8.66 -0.04 (-0.46%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It also offers wheelchairs, hospital beds, oxygen concentrators, CPAP masks and related supplies, wound care supplies, diabetes management supplies, wheelchair cushion accessories, orthopedic bracing, breast pumps and supplies, walkers, commodes and canes, and nutritional and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. The company is headquartered in Plymouth Meeting, Pennsylvania.CareDx NASDAQ:CDNA$15.17 +0.17 (+1.13%) Closing price 04:00 PM EasternExtended Trading$15.08 -0.10 (-0.63%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Viemed Healthcare NASDAQ:VMD$7.33 -0.04 (-0.54%) Closing price 04:00 PM EasternExtended Trading$7.33 0.00 (0.00%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viemed Healthcare, Inc., together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment; and sells and rents HME devices. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.Viridian Therapeutics NASDAQ:VRDN$13.12 -0.50 (-3.67%) Closing price 04:00 PM EasternExtended Trading$13.13 +0.01 (+0.07%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Monster Beverage Stock: Short Report Risks vs Upside Potential Onsemi Stock Confirms Bottom, But What’s the Upside? 3 Reasons Tesla Should Be a $300 Stock by June Amazon: Why The Great Comeback Rally Could Be About to Begin Is Reddit Stock a Buy, Sell, or Hold After Earnings Release? MarketBeat Week in Review – 04/28 - 05/02 ExxonMobil: Production Offset Prices, Capital Return Safe in 2025 Warning or Opportunity After Super Micro Computer's Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
